U.S. Markets closed

KaloBios Pharmaceuticals, Inc. (KBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.65+0.05 (+3.12%)
At close: 2:41PM EDT
People also watch

KaloBios Pharmaceuticals, Inc.

1000 Marina Boulevard
Suite 250
Brisbane, CA 94005
United States

Full Time Employees17

Key Executives

Dr. Cameron Durrant M.D., MBAChairman and Chief Exec. Officer516.83kN/A57
Mr. David L. Tousley M.B.A., CPAInterim Chief Financial Officer333.79kN/A61
Mr. Morgan LamChief Scientific Officer427.5kN/A52
Mr. Edward Painter MBAHead of Communications and Investor RelationsN/AN/AN/A
Mr. Patrick CrutcherHead of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States. Its lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems. The company is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is based in Brisbane, California.

Corporate Governance

KaloBios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.